title: Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.
abstract: BACKGROUND
  Current vaccines to avian influenzae virus (AIV), a highly contagious disease of birds, need to be constantly updated due to the high level of variation in the target antigens. Therefore, a vaccine that could induce broad cross protection against AIV is required. The M2 membrane protein is structurally conserved amongst AIV subtypes but tends in induce a poor immune response, whereas C3d has been shown in many species to enhance immunogenicity. In this study, we investigated the potential of M2-avian C3d fusion proteins to provide effective immunity.
  
  
  RESULTS
  We fused chicken complement C3d to sM2 (M2 protein with the transmembrane region deleted) of AIV and expressed four fusion proteins, GST (Glutathione S-transferase tagged proteins in pGEX expression vector) -C3d-sM2, GST-C3d-L2-sM2, GST-C3d-L1-C3d-sM2 and GST-C3d-L1-C3d-L2-sM2 were used to immunize mice. In addition, Specific pathogen free (SPF) chickens were inoculated with the plasmids pcDNA-sM2, pcDNA-C3d-L1-C3d-L2-sM2, GST-sM2 and GST-C3d-L1-C3d-L2-sM2. The immune response was monitored by an enzyme-linked immunosorbent assay (ELISA) for sM2 antibody, and all the test animals were challenged with A/chicken/Bei Jing/WD9/98 (H9N2) virus. Results revealed that the anti-sM2 antibody in mice and chickens vaccinated with these proteins was higher than the nonfused forms of sM2, the GST-C3d-L1-C3d-L2-sM2 groups have conferred the highest 30% and 20% protection ratio in mice and chickens respectively. In addition, the pcDNA-C3d-L1-C3d-L2-sM2 also enhances the antibody responses to sM2 compared to pcDNA-sM2 in chickens, and acquired 13.3% protection ratio.
  
  
  CONCLUSIONS
  These results indicated that chicken C3d enhanced the humoral immunity against AIV M2 protein either fused proteins expressed by the prokaryotic system or with the DNA vaccine. Nevertheless, in view of the poor protection ratio for these animals, we speculated that this is not a worthy developing of vaccine in these constructs.
authors.affiliation: College of Animal Medicine, China Agricultural University, Beijing, China.
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Zhang
authors.forename: Yongqing
authors.initials: Y
authors.lastname: Li
authors.forename: Shufang
authors.initials: S
authors.lastname: Xu
authors.forename: Fuyong
authors.initials: F
authors.lastname: Chen
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Beiyu
authors.initials: B
authors.lastname: Jiang
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Chen
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D002645:Chickens; D015933:Complement C3d / Q000235:genetics / Q000276:immunology*; D006224:Cricetinae; D056724:Immunity, Humoral; D009980:Influenza A virus / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D005585:Influenza in Birds / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D011201:Poultry Diseases / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D011897:Random Allocation; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D013047:Specific Pathogen-Free Organisms; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology*; D000086082:Viroporin Proteins
chemical_list: D000914:Antibodies, Viral; D015933:Complement C3d; D007252:Influenza Vaccines; D011993:Recombinant Fusion Proteins; D014763:Viral Matrix Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins
references.citation: Vet Immunol Immunopathol. 2001 Nov;83(1-2):79-92
references.pmid: 11604163
references.citation: Nat Immunol. 2000 Aug;1(2):127-31
references.pmid: 11248804
references.citation: Curr HIV Res. 2005 Apr;3(2):191-8
references.pmid: 15853723
references.citation: Avian Pathol. 2008 Oct;37(5):477-85
references.pmid: 18798021
references.citation: J Immunol. 2010 Mar 1;184(5):2233-5
references.pmid: 20164433
references.citation: Int Arch Allergy Immunol. 2004 Aug;134(4):310-23
references.pmid: 15218334
references.citation: J Immunol. 2004 May 15;172(10):5833-7
references.pmid: 15128761
references.citation: Nat Biotechnol. 1998 May;16(5):458-62
references.pmid: 9592395
references.citation: Clin Exp Immunol. 1996 Jun;104(3):531-7
references.pmid: 9099940
references.citation: Dev Comp Immunol. 2005;29(10):907-15
references.pmid: 15978284
references.citation: AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):829-35
references.pmid: 11429124
references.citation: Immunol Res. 2005;33(2):103-12
references.pmid: 16234578
references.citation: J Immunol. 1999 Apr 15;162(8):4377-80
references.pmid: 10201971
references.citation: Blood. 2000 Apr 15;95(8):2617-23
references.pmid: 10753842
references.citation: Immunology. 2000 May;100(1):4-12
references.pmid: 10809953
references.citation: Vaccine. 1999 May 4;17(18):2237-44
references.pmid: 10403591
references.citation: Proc Natl Acad Sci U S A. 1985 Jun;82(12):4235-9
references.pmid: 2408276
references.citation: J Immunol. 2002 Dec 15;169(12):6935-44
references.pmid: 12471127
references.citation: J Immunol Methods. 2001 Dec 1;258(1-2):97-109
references.pmid: 11684127
references.citation: Science. 1996 Jan 19;271(5247):348-50
references.pmid: 8553069
references.citation: Virol J. 2010 Jan 18;7:9
references.pmid: 20082709
references.citation: Immunol Res. 1998;17(1-2):109-21
references.pmid: 9479573
references.citation: Vaccine. 1995;13(15):1399-402
references.pmid: 8578816
references.citation: Vaccine. 2003 Jun 2;21(19-20):2616-26
references.pmid: 12744898
references.citation: Immunol Cell Biol. 2010 Feb;88(2):228-32
references.pmid: 19935770
references.citation: J Immunol. 2001 Jul 1;167(1):163-72
references.pmid: 11418645
references.citation: Trends Microbiol. 2003 Oct;11(10):449-52
references.pmid: 14557025
references.citation: J Virol. 2004 May;78(9):4710-9
references.pmid: 15078953
references.citation: Vaccine. 2004 Apr 16;22(13-14):1764-72
references.pmid: 15068860
references.citation: Vaccine. 2001 Oct 12;20(1-2):242-8
references.pmid: 11567770
references.citation: J Virol. 2003 Feb;77(3):2046-55
references.pmid: 12525639
references.citation: Vaccine. 2003 Feb 14;21(9-10):902-14
references.pmid: 12547601
references.citation: Nat Med. 1999 Oct;5(10):1157-63
references.pmid: 10502819
references.citation: PLoS One. 2010 Mar 23;5(3):e9812
references.pmid: 20352112
references.citation: J Immunol. 1994 Feb 15;152(4):1727-37
references.pmid: 8120381
references.citation: Vaccine. 2004 Apr 16;22(13-14):1773-81
references.pmid: 15068861
references.citation: Infect Immun. 2005 Nov;73(11):7311-6
references.pmid: 16239528
references.citation: Vaccine. 1997 Jun;15(8):827-9
references.pmid: 9234525
references.citation: J Immunol. 2005 Dec 15;175(12):8011-23
references.pmid: 16339538